Beryllium hypersensitivity and chronic beryllium lung disease

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 2, 2009, Pages 165-169

  Santo Tomas, Linus H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Berylliosis; Beryllium; Granuloma; Hypersensitivity; Occupational lung disease

Indexed keywords

BERYLLIUM; CHEMOKINE; HLA DPB1 ANTIGEN; STEROID;

BERYLLIUM HYPERSENSITIVITY; BERYLLIUM LYMPHOCYTE PROLIFERATION TEST; CHRONIC BERYLLIUM LUNG DISEASE; CHRONIC LUNG DISEASE; DISEASE PREDISPOSITION; DRUG MEGADOSE; FUNCTION TEST; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GRANULOMATOSIS; HUMAN; HYPERSENSITIVITY; LYMPHOCYTE; OCCUPATION; OCCUPATIONAL EXPOSURE; PATHOGENESIS; REVIEW; RISK; SARCOIDOSIS; SENSITIZATION;

AIR POLLUTANTS, OCCUPATIONAL; BERYLLIOSIS; BERYLLIUM; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; RESPIRATORY HYPERSENSITIVITY; RISK FACTORS;

EID: 62349097227     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283218341     Document Type: Review

References (37)

1. Madl AK, Unice K, Brown JL, et al. Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant. J Occup Environ Hyg 2007; 4:448-466. The study employs five approaches to reconstructing exposure of workers and its influence on exposure and response patterns. Provides support for lower occupational exposure limits.
2. Cummings KJ, Deubner DC, Day GA, et al. Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers. Occup Environ Med 2007; 64:134-140. This is an example of how a program can further reduce occupational morbidity. The measures taken are worth replicating.
3. Stanton ML, Henneberger PK, Kent MS, et al. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J Occup Environ Med 2006; 48:204-211.
4. Maier LA, Martyny JW, Liang J, Rossman MD. Recent chronic beryllium disease in residents surrounding a beryllium facility. Am J Respir Crit Care Med 2008; 177:1012-1017.
5. Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993; 148:985-991.
6. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease, a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171:54-60.
7. Borak J, Woolf SH, Fields CA. Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: an evidence-based assessment. J Occup Environ Med 2006; 48:937-947.
8. Middleton DC, Fink J, Kowalski PJ, et al. Optimizing BeLPT criteria for beryllium sensitization. Am J Ind Med 2008; 51:166-172. The study sets the argument for doing the BeLPT twice except in populations of high prevalence. The tables on calculated positive predictive value of the test based on prevalence rates can be useful.
9. Fireman E, Haimsky E, Noiderfer M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:144-148.
10. Muller-Quernheim J, Gaede KI, Fireman E, Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006; 27:1190-1195.
11. Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol 2005; 26:543-549.
12. McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epiderniol 2003; 157:388-398.
13. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001; 74:167-176.
14. 3. Am J Ind Med 1996; 30:16-25.
15. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989; 31:603-608.
16. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993; 35:267-274.
17. Amicosante M, Sanarico N, Berretta F, et al. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol 2001; 62:686-693.
18. Maier LA, McGrath OS, Sato H, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003; 171:6910-6918.
19. Rossman MD, Stubbs J, Lee CW, et al. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002; 165:788-794.
20. McCanlies EC, Ensey JS, Schuler CR, et al. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004; 46:95-103.
21. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262:242-244.
22. Silver K, Sharp RR. Ethical considerations in testing workers for the - Glu69 marker of genetic susceptibility to chronic beryllium disease. J Occup Environ Med 2006; 48:434-443.
23. Amicosante M, Berretta F, Rossman M, et al. Identification of HLA-DRPhe-beta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlu-beta69. Respir Res 2005; 6:94.
24. Sato H, Spagnolo P, Silveira L, et al. BTNL2 allele associations with chronic beryllium disease in HLA-DPBI*Glu69-negative individuals. Tissue Antigens 2007; 70:480-486.
25. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001; 18:677-684.
26. McCanlies EC, Schuler CR, Kreiss K, et al. TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization. J Occup Environ Med 2007; 49:446-452. Results are at variance with a previous study implicating TNF polymorphisms in the genetic susceptibility to CBD.
27. Sato H, Silveira L, Fingerlin T, et al. TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization. J Allergy Clin Immunol 2007; 119:687-696. As with the previous reference, the results are at variance with an earlier study implicating TNF polymorphisms in the genetic susceptibility to CBD.
28. Amicosante M, Fontenot AP. T cell recognition in chronic beryllium disease. Clin Immunol 2006; 121:134-143.
29. Saltini C, Amicosante M, Franchi A, et al. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998; 12:1463-1475.
30. Palmer BE, Mack DG, Martin AK, et al. CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease. J Allergy Clin Immunol 2007; 120:184-191. In further elucidation of particular T-cell line roles, this study identifies a marker that may reflect severity of disease and inflammation in CBD.
31. Hong-Geller E, Pardington PE, Cary RB, et al. Chemokine regulation in response to beryllium exposure in human peripheral blood mononuclear and dendritic cells. Toxicology 2006; 218:216-228.
32. Rodriguez S, Kunde YA, McCleskey TM, Hong-Geller E. Upregulation of I-CAM1 in response to beryllium exposure in small airway epithelial cells. Toxicol Lett 2008; 179:140-147.
33. Fontenot AP, Edwards DM, Chou YK, et al. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease. Eur J Immunol 2006; 36:930-939.
34. Sawyer RT, Fontenot AP, Barnes TA, et al. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol 2007; 36:191-200.
35. Dobis DR, Sawyer RT, Gillespie MM, et al. Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med 2008; 177:1002-1011. An interesting investigation and methodology that opens new doors for research on other mediators of oxidative stress and the possible therapeutic role of antioxidants in CBD.
36. Nagaoka K, Yoshida T, Sakakibara H, et al. Significant improvement from chronic beryllium disease following corticosteroid pulse therapy. Ind Health 2006; 44:296-301.
37. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004; 126: 2000-2007.